Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01797367 · ClinicalTrials.gov registry record
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 1,026
- Enrollment target
NCT01797367 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 1,026 participants.
The verdict
NCT01797367 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 1,026 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if starting anti-retroviral therapy (ART) above 500 cluster-of-differentiation-4 (CD4)+ cells/milliliter (mL) ('early ART group') slows the rate of decrease in lung function over time compared to waiting to start ART until the CD4+ drops below 350 cells/mL ('deferred ART group'). Lung function normally declines with age, and both human immunodeficiency virus (HIV) infection and ART have been shown to case a decline in lung function as well. Decline in lung function can be an early indicator of chronic obstructive pulmonary disease (COPD), a significant cause of sickness and death in people with HIV. In this study, lung function will be measured at baseline and every year thereafter by using a spirometer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,026 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01797367
The ClinicalTrials.gov registry entry for NCT01797367 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,026 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01797367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01797367 about?
NCT01797367 is a clinical study titled "Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)". The purpose of this study is to find out if starting anti-retroviral therapy (ART) above 500 cluster-of-differentiation-4 (CD4)+ cells/milliliter (mL) ('early ART group') slows the rate of decrease in lung function over time compared to waiting to start ART until the CD4+ drops below 350 cells/mL ('...
What is the current status of trial NCT01797367?
This trial is currently completed. The enrollment target is 1,026 participants. The study started on 2010-03. Estimated completion is 2016-12-31.
Who is sponsoring clinical trial NCT01797367?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.